Clinical Trials Browser

Phase 1/2 × Doxorubicin × Dermatologic × Clear all

Cutaneous Squamous Cell Carcinoma

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT01198665 2015-03-03

RADCHOP

Phase 1/2 Completed

46 enrolled

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT00787527 2014-09-09

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Phase 1/2 Completed

14 enrolled 8 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Clinical Trials

cSCC

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

RADCHOP

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma